Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.

被引：0
|
作者：
Gazzoni, Gabriela
Vilbert, Maysa
Oliveira, Joao Pedro
Dacoregio, Maria Inez
Michelon, Isabella
Reis, Pedro
Braga, Marcelo
Simoes, Clara
Oliveira, Lilia
Cardoso, Ana Paula Garcia
机构：
[1] Hosp Servidor Publ Estadual, Sao Paulo, Brazil
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[4] Univ Estadual Ctr Oeste UNICTR, Guarapuava, Brazil
[5] Univ Catolica Pelotas, Pelotas, RS, Brazil
[6] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[7] Fac Multivix, Vitoria, Brazil
[8] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[9] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review
    Malik, Rhea
    Xiang, David H.
    Riew, Grant J.
    Sanchez-Melendez, Stephanie
    Afvari, Shawn
    Leboeuf, Nicole R.
    Nambudiri, Vinod E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04)
  • [22] Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study
    Shindo, Tetsuya
    Hashimoto, Kohei
    Kenuka, Toshiki
    Miyamoto, Shintaro
    Hiyama, Yoshiki
    Fukuta, Fumimasa
    Kunishima, Yasuharu
    Okada, Manabu
    Matsukawa, Masanori
    Kato, Ryuichi
    Senda, Masaya
    Wanifuchi, Atsushi
    Sato, Shunsuke
    Kobayashi, Ko
    Tanaka, Toshiaki
    Masumori, Naoya
    JOURNAL OF GERIATRIC ONCOLOGY, 2025, 16 (02)
  • [23] In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity
    Molina, Gabriel E.
    Schwartz, Ben
    Srinivas, Sandy
    Shah, Sumit
    Zaba, Lisa C.
    EUROPEAN UROLOGY, 2023, 83 (04) : 377 - 378
  • [24] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Takahashi, Shunji
    Uemura, Motohide
    Kimura, Tomokazu
    Kawasaki, Yoshihide
    Takamoto, Atsushi
    Yamaguchi, Akito
    Melhem-Bertrandt, Amal
    Gartner, Elaina M.
    Inoue, Takashi
    Akazawa, Rio
    Kadokura, Takeshi
    Tanikawa, Toshiki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
  • [25] Reno-vascular toxicities associated with carfilzomib: Systematic review and meta-analysis.
    Shah, Chintan
    Bejjanki, Harini
    Bishnoi, Rohit
    Jain, Ankur
    Samal, Subhankar
    Moreb, Jan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Shunji Takahashi
    Motohide Uemura
    Tomokazu Kimura
    Yoshihide Kawasaki
    Atsushi Takamoto
    Akito Yamaguchi
    Amal Melhem-Bertrandt
    Elaina M. Gartner
    Takashi Inoue
    Rio Akazawa
    Takeshi Kadokura
    Toshiki Tanikawa
    Investigational New Drugs, 2020, 38 : 1056 - 1066
  • [27] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Khaki, Ali Raza
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Shah, Sumit
    Zakharia, Yousef
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Grivas, Petros
    Gupta, Shilpa
    Hoimes, Christopher J.
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma
    Brown, Jacqueline T.
    Nazha, Bassel
    Liu, Yuan
    Lozada, Kelsea
    Smith, Jeremy D.
    Hartman, Caitlin
    McClintock, Greta Russler
    Kucuk, Omer
    Carthon, Bradley Curtis
    Harvey, R. Donald
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.
    Brown, Jacqueline T.
    Nazha, Bassel
    Liu, Yuan
    Ranbhise, Shreya
    Lozada, Kelsea
    Hartman, Caitlin
    McClintock, Greta Russler
    Kucuk, Omer
    Carthon, Bradley Curtis
    Harvey, R. Donald
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 609 - 609
  • [30] Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
    Bantounou, Maria A.
    Plascevic, Josip
    MacDonald, Lewis
    Wong, Man Chun
    O'Connell, Neasa
    Galley, Helen F.
    CURRENT UROLOGY, 2023, 17 (04) : 271 - 279
12345